HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and lowers the price target from $3 to $2.5.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and lowers the price target from $3 to $2.5.